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Abstract
Background: The risk of male-to-female intravaginal HIV-1 transmission is estimated at about 1 event per 200–2000 coital
acts. The aim of this study was to assess the residual risk of HIV presence in semen in patients under HAART therapy.
Methods and Findings: The study took place in France from October 2001 to March 2009. 394 paired blood and semen
samples were provided from 332 HIV-1 infected men. The Roche Cobas AMPLICOR Monitor HIV assay was used to quantify
HIV-1 RNA in blood and in seminal plasma. Three percent of 394 HIV-1 infected men enrolled in an assisted reproductive
technology program harbored detectable HIV-1 RNA in semen, although they had no other sexually transmitted disease and
their blood viral load was undetectable for at least 6 months under antiretroviral treatment.
Conclusion: These data suggest that undetectable plasma HIV RNA means a lower risk of viral transmission through seminal
fluid on a population level, but not necessarily at the level of the individual.
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Introduction
HIV-1, the causative agent of AIDS, has infected about 33
million people and caused over 20 million deaths (UNAIDS data).
More than 80% of these HIV-1 infections are acquired through
sexual intercourse. Despite its dramatic spread in the human
population, the efficiency ofHIV-1transmission via thesexualroute
is surprisingly poor. For instance, the risk of male-to-female
intravaginal HIV-1 transmission is estimated at about 1 event per
200–2000 coital acts [1]. Globally, most infections result from
genital exposure to semen (SE) of HIV-positive men [2]. Women
who acquired HIV-1 through vaginal intercourse constitute almost
60%of new infectionsinAfrica [3]. Protected intercourseis strongly
recommended for HIV-serodiscordant couples in all circumstances.
Some leading researchers have suggested that effective HIV
treatment essentially renders a patient non-infectious. Previous data
published by the Swiss Federal Commission for HIV/AIDS
suggested that seropositive individuals, with no other sexually
transmitted disease, on antiretroviral therapy, with undetectable
viral loads for .6 months, do not transmit HIV [4]. In order to
avoid the risk of HIV sexual transmission to women, when men are
infected, HIV-serodiscordant couples now have access to assisted
reproductive technology (AR) programs in several countries. These
programs vary in the assisted reproductive technology methods
chosen (intrauterine insemination, in-vitro fertilization, intracyto-
plasmic sperm injection) and in the type of sperm preparation used
(density gradient migration alone or followed by swim-up). Good
rates of pregnancy are reported when the male partner is infected
(63%) and no seroconversion has been reported to date [5]. The
infectiousness of HIV-1 in male genital fluid together with the
susceptibility of the host, the type of sexual practice, and viral load
are major determinants of sexual transmission [6]. The factors
modulating HIV infectiousness in semen are poorly understood [7].
Several factors can interfere and may have the potential to increase
risk, such as fluctuation of adherence, drug characteristics
influencing penetration into compartments, and asymptomatic
and undiagnosed STDs. Moreover, compartmentalization of HIV
replication in semen has been demonstrated for some men and,
therefore, HIV blood viral load might not always reflect HIV
replication levels in semen [8,9]. Although HAART reduces HIV
loads in both blood and seminal compartments, low levels of HIV
RNA can still be detected in seminal plasma and HIV-infected cells
can be recovered in nonsperm cells, even in those who have
undergone prolonged successful treatment [10,11]. A recent study,
demonstrated that HIV may still be present and potentially
infectious in semen, even if it is undetectable in blood [12]. The
aim of this study is to assess the residual risk of HIV presence in
semen in patients under HAART therapy.
Materials and Methods
Patients
Since 2001, our centre has managed HIV-1-serodiscordant
couples with a male infected partner to allow pregnancies with
assisted reproduction using sperm washing. Three hundred and
thirty-two HIV-1 infected men attending the Laboratory IVF
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the French law (no HIV related active disease, a regular follow up
and CD4 counts .200 mm3 repeated at least twice during the last
6 month and a blood viral load ,10 000 copies/ml stable during
the last 6 month) after they gave their fully informed consent.
Characteristics of patients were: mean age 6 Sd 3964 years, HIV
mode of transmission (54% intravenous drug use, 41% sexual, and
5% blood transfusion), median known treatment duration, 11.5
years.
As this study included only patients issued from routine follow
up, declaration to ethic committee is not mandatory, as
recommended by the French Government Rules.
Samples
Overall 394 paired blood and semen samples were provided
between October 2001 and March 2009 (median time difference
between blood and semen samples was 28 days). The number of
samplesprovidedbythepatientsvariedbetweenonetofour.Plasma
samples were separated from blood by centrifugation and frozen at
280uC until use. After 2–5 days of sexual abstinence, semen
samples were obtained by masturbation into a sterile container and
wereprocessedwithin1 h of ejaculation.If availableonemilliliterof
the semen sample was centrifuged at 8006g for 10 min through a
two-layer discontinuous gradient (2 ml of 40, and 90% of
SupraSperm, Medicult, France). The seminal plasma (supernatant)
was separated and stored at 280uC until further use. The motile
spermatozoa fraction were recovered from the 90% fraction and
washed once with an equal volume of BM1 medium (Eurobio,
France). The resulting centrifugation pellet was resuspended and
observed by microscope to count them and to check for the absence
of white blood cell contamination. Thismotilespermatozoa fraction
was frozen at 280uC as aliquots of 500,000 cells until use.
Detection of HIV RNA in blood plasma
HIV RNA in blood plasma was detected by Cobas Taqman
AMPLICOR HIV assay (Roche Diagnostics, Meylan, France),
according to the instructions of the manufacturer. Sensitivity of the
quantitative assay was 40 copies/ml (1.6 log)[13].
Detection of HIV RNA in seminal plasma
RNA extraction was performed using silica beads (NucliSens
[Organon Teknika S.A., Fresnes, France]) For HIV RNA we used
500 ml of thawed fraction 1 and 6.7 ml of the internal control from
the Roche Cobas AMPLICOR Monitor HIV assay. The eluted
sample was diluted with specimen diluent of Roche Amplicor
Monitor HIV kit to obtain 100 ml of sample in a new tube.
The sensitivities of the quantitative assays were determined by
using serial 2-fold dilutions (from 320 to 20 copies/ml) or 10-fold
dilutions (from 4 000 to 4 copies/ml), respectively, in HIV-
negative seminal plasma of blood plasma from an HIV-infected
patient, which had been quantified previously by the Cobas
AMPLICOR Monitor HIV assay. Then, each dilution was
extracted and tested in six independent experiments. Sensitivity
of the quantitative assay was 40 copies/ml (1.6 log) [13].
Results and Discussion
Figure 1 represents the study flowchart. Among the 394 paired
samples, HIV-1 was detectable in 131 (33%) blood plasma samples
and the median level of HIV-1 RNA in blood was 468 copies/ml
(range=50–10 400). HIV-1 was detectable in 29 (7%) of seminal
plasma samples and the median level of HIV-1 RNA in semen was
1360 copies/ml (range [73–435 000]). Overall, 272 (69%) paired
samples were concordant between blood plasma and seminal
plasma for HIV-1 detection (inter-rater agreement k=0.12
[20.01;0.25]); 253 (64%) samples were HIV-1 negative both in
blood plasma and seminal plasma, and 19 (5%) samples were
HIV-1 positive both in blood plasma and seminal plasma. Overall,
122 (31%) paired samples were discordant between blood plasma
and seminal plasma for HIV-1 detection. Among these, 10 (3%)
seminal plasma samples had detectable HIV-1 RNA although
blood viral load was undetectable for at least 6 months under
antiretroviral treatment (Table 1). Note that the median HIV-1
Figure 1. Study flowchart.
doi:10.1371/journal.pone.0010569.g001
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(median 1545, range [576–23 000]). This does not seem to be
related to a specific treatment, because these patients were treated
by various therapies comprising a non-nucleoside reverse tran-
scriptase inhibitor or protease inhibitor-based regimen, with, in
some cases, antiretroviral drugs known to have good penetration
into genital compartments [14]. Note that diffusion of antiretro-
viral drugs into genital compartment is highly variable. NRTIs
have a good penetration with plasma/genital secretion ratio
around 100% and more for the most common used (3tc, ftc, tdf,
abc, azt). Nevirapine present also a good penetration (around
80%) in comparison with efavirenz (,1%). Among PI, only IDV
who presents a lower protein bound fraction had a higher plasma/
genital secretion ratio (100–200%) than the others for which the
ratio is below 50% and less. New drugs, such raltegravir and
maraviroc appear to have a good penetration ratio (70 to more
than 200%) in these compartments [14,15].
A recent study tried to link between the seminal viral load and
HIV transmission. It indicated that the risk of HIV transmission
from male to female is related to genital HIV-1 RNA concentra-
tions. It was shown that the rate of HIV sero-incidence increased as
well as the HIV seminal plasma concentrations increased: each
increasing of HIV viral load of 1 log c/ml in the plasma seminal
increased by 61.85 the risk of HIV transmission [16].
Previous studies have already shown that intermittent HIV
RNA shedding can occur in semen from treated patients with
undetectable HIV viral load in blood [9,13,17]. Our results
confirm those of Marcelin et al. on 257-paired blood and semen
samples followed for greater than 6 months [12]. In this study, 225
were concordant with undetectable HIV levels in blood and semen
and 9 had detectable levels of HIV in both blood and semen.
Interestingly, 23 samples had HIV viral loads detectable in blood
but not semen and 7 samples had undetectable viral load levels in
blood but detectable virus in the semen (5%) (sensitivities of the
assay for detecting HIV in blood and in semen were 40 cp/ml and
200 cp/ml respectively) [12]. Our results also confirm a study by
Sheth et al. on 25 patients with undetectable blood HIV RNA
measurements 16 weeks after HAART initiation (sensitivity of the
assay for detecting HIV in blood was 50 cp/ml) [18]. Isolated HIV
shedding in semen was detectable in 12 of 25 patients despite
effective HAART therapy, and at a high level (.5000 copies/mL)
in 4 of 25 participants. Semen isolates did not contain drug
resistant virus and the HIV detected was infectious in vitro. The
only measurement that seemed to predict the presence of
persistent HIV in semen despite HAART was pre-HAART semen
HIV levels. A recent finding is that Amyloidogenic PAP fragments
are abundant in seminal fluid and boost semen-mediated
enhancement of HIV infection. Thus, they may play an important
role in sexual transmission of HIV [19]. Another recent study
highlights the residual risk of HIV-1 transmission during
unprotected intercourse and raises the question of the possible
consequences of ineffective HAART in the genital tract [20].
In conclusion, between 3% (the present study) to 5% of patients
with undetectable HIV levels in blood had detectable levels of
HIV in semen [12]. These data, suggest that undetectable plasma
HIV RNA means a lower risk of viral transmission through
seminal fluid on a population level but not necessarily at the level
of the individual.
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